Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old

Starting soon · Phase 2

Conditions studied: Congenital Adrenal Hyperplasia

In brief

The main objective of this study is to assess the safety and tolerability of crinecerfont in pediatric participants 3 months to \<4 years of age with CAH.

Key facts

Study ID

NCT07536269

Run by

Neurocrine Biosciences

People needed

20

Starts

2026-04-01

Expected to finish

2028-03-01

Last updated by the study team

2026-04-17

Who can join

Age: 0 and older, up to 4. Sex: any. Healthy volunteers: not accepted.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.